Ali Mohtashim, Aima Azhar, Saad Mazhar, Deepa Devi, Muhammad Danial, Dhruvilkumar Patel, Owais Khan, Anushka Andani, Muhammad Mohib Khan, Shahzaib Samad, Aena Qureshi, Hafsa Ali, Umer Ejaz, Sayed Jawad
BACKGROUND: The optimal treatment regimen for patients with Hughes syndrome remains unclear. Therefore, the authors sought to compare the outcomes of warfarin vs. factor Xa inhibitors in patients with Hughes syndrome. METHODS: MEDLINE, Embase, and Cochrane Central databases were searched for randomized controlled trials (RCTs) comparing 8 efficacy and safety of warfarin and factor Xa inhibitors in patients with Hughes syndrome. Recurrent thrombosis, all-cause mortality, stroke, adverse reactions, and bleeding were among 10 outcomes of interest...
May 2024: Annals of Medicine and Surgery